Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 6

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 6
---
pline results from our KP1077 Phase 2                                                                                                                                                 
 trial in idiopathic hypersomnia at the 2024 Annual SLEEP Meeting. At the end of the third quarter, we completed our end-of-Phase 2 meeting. The FDA and Zevra reached                                                                                  
 alignment on a Phase 3 trial design and indicated that a single pivotal study with appropriate confirmatory evidence would be sufficient to submit a New Drug Application (NDA). As part of our pipeline review, we have determined that the best path 
 forward to maximize the value of KP1077 is to explore strategic alternatives for advancing its clinical development and future commercialization.                                                                                                      |

| 3. | Optimizing Leadership Team with the Right Talent: As we have continued our momentum, we have also                                              
 evolved our leadership team to ensure we have the right talent to support our continued growth into a leading rare disease commercial company. |

| • |     | In June 2024, we enhanced our executive leadership team with the appointments of Rahsaan Thompson as Chief                                                                                                 
 Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer; we also consolidated our development and scientific functions under Adrian Quartel, our Chief Medical Officer. |

| 4. | Strengthening Zevra’s Corporate Foundation: We have continued our approach of disciplined capital                       
 allocation, focusing our investments on the highest return activities and actively enhancing our financial flexibility. |

| • |     | In April 2024, we bolstered Zevra’s balance sheet by restructuring the Company’s debt, using a 
 new credit facility provided by premier biotech investors.                                     |

| • |     | In September 2024, we secured a Rare Pediatric Disease Priority Review Voucher (PRV) with the                                                                                                                                
 approval of MIPLYFFA, which we sold this April for approximately $150 million, providing additional non-dilutive capital to fuel our commercial launches of MIPLYFFA and OLPRUVA, and                                        
 further the development of celiprolol. We believe this transaction provides us with important financial flexibility to deliver on our strategic plan without undue reliance on incremental funding from the capital markets. |

In the coming quarters, your Board and management team intend to maintain focus on accelerating Zevra’s momentum – continuing to drive value for both rare disease patients and our stockholders. Your Board and Management Team Have a Clear Path Forward to Continue Zevra’s Momentum Looking ahead, we have a clear strategic plan and path forward to continue Zevra’s growth